80
Participants
Start Date
October 1, 2021
Primary Completion Date
September 30, 2024
Study Completion Date
December 30, 2026
Toripalimab (anti-programmed death-1 inhibitor)
The participants will receive two cycles of Toripalimab, with 21 days each. 240mg of Toripalimab will be used intravenously on the first day of each cycle.
Albumin paclitaxel
The participants will receive two cycles of Albumin paclitaxel, with 21 days each. 260mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
Cisplatin
The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m\^2 of Cisplatin will be used intravenously on the first day of each cycle.
Docetaxel
The participants will receive two cycles of Docetaxel, with 21 days each. 75mg/m\^2 of Docetaxel will be used intravenously on the first day of each cycle.
5-Fluorouracil
The participants will receive two cycles of 5-Fluorouracil, with 21 days each. 750mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
RECRUITING
Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai Jiao Tong University School of Medicine
OTHER